156 research outputs found
Genetic and molecular biomarkers of Alzheimer's disease
[eng] Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Research in the past decade has led to major progress in understanding the genetic etiology of the disease; since I started my PhD (2019), nearly 20 genetic risk factors have been associated with late onset AD. Among them, the Ԑ4 allele of the APOE gene was the first identified, and remains the major genetic risk factor for AD. Despite extensive genetic research, a large part of the disease heritability remains elusive, the disease mechanisms incomprehensible, and targeted preventive interventions or pharmacological treatments for AD unavailable at the time. In this context, the overarching aim of the studies included in this thesis was to contribute to the knowledge of AD identifying new genetic risk factors and to better understand the role played by the APOE gene in the development of the disease. Such information would allow us to gain new insights into the molecular and biological mechanisms underlaying the disease and ultimately find new targets for treatment. This thesis provides evidence of the possible effectiveness of the use of a polygenic risk scores in a clinical setting for diagnosis of AD and actively improves the knowledge of the genetic factors associated with AD through genome-wide association studies
Epilepsy in Neurodegenerative Diseases: Related Drugs and Molecular Pathways
Alzheimer’s disease; Huntington’s disease; Parkinson’s diseaseEnfermedad de Alzheimer; Enfermedad de Huntington; Enfermedad de ParkinsonMalaltia d'Alzheimer; Malaltia de Huntington; Malaltia de ParkinsonEpilepsy is a chronic disease of the central nervous system characterized by an electrical imbalance in neurons. It is the second most prevalent neurological disease, with 50 million people affected around the world, and 30% of all epilepsies do not respond to available treatments. Currently, the main hypothesis about the molecular processes that trigger epileptic seizures and promote the neurotoxic effects that lead to cell death focuses on the exacerbation of the glutamate pathway and the massive influx of Ca2+ into neurons by different factors. However, other mechanisms have been proposed, and most of them have also been described in other neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, or multiple sclerosis. Interestingly, and mainly because of these common molecular links and the lack of effective treatments for these diseases, some antiseizure drugs have been investigated to evaluate their therapeutic potential in these pathologies. Therefore, in this review, we thoroughly investigate the common molecular pathways between epilepsy and the major neurodegenerative diseases, examine the incidence of epilepsy in these populations, and explore the use of current and innovative antiseizure drugs in the treatment of refractory epilepsy and other neurodegenerative diseases.A.C. acknowledges the support of the Spanish Ministry of Science, Innovation and Universities under the grant Juan de la Cierva (FJC2018-036012-I). Authors acknowledge the support of the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated into the Spanish National R+D+I Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER “Una manera de hacer Europa”) grant PI17/01474 awarded to M.B. Boada, grant PI19/00335 awarded to M.M. and the European Social Fund (ESF “Investing in your future”) for the Sara Borrell Contract (CD19/00232) to SA-L; M.E. acknowledges the support of the Spanish Ministry of Economy and Competitiveness under the project SAF2017-84283-R, and CIBERNED under project CB06/05/0024. E.B.S. acknowledges the support of the Portuguese Science and Technology Foundation (FCT) for the strategic fund (UIDB/04469/2020). A.R. acknowledges the support of CIBERNED (Instituto de Salud Carlos III (ISCIII)), the EU/EFPIA Innovative Medicines Initiative Joint Undertaking, ADAPTED Grant Nº 115975, from EXIT project, EU Euronanomed3 Program JCT2017 Grant Nº AC17/00100, from PREADAPT project. Joint Program for Neurodegenerative Diseases (JPND) Grant No. AC19/00097, and from grants PI13/02434, PI16/01861 BA19/00020, and PI19/01301. Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by Instituto de Salud Carlos III (ISCIII)- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de Hacer Europa”), by Fundación bancaria “La Caixa” and Grífols SA (GR@ACE project)
Common variants in Alzheimer's disease and risk stratification by polygenic risk scores
Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease
Common Variants in Alzheimer’s Disease and Risk Stratification by Polygenic Risk Scores
Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n=409,435 and validation size n=58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease.The present work has been performed as part of the doctoral program of I. de Rojas at the
Universitat de Barcelona (Barcelona, Spain) supported by national grant from the
Instituto de Salud Carlos III FI20/00215. The Genome Research @ Fundació ACE project
(GR@ACE) is supported by Grifols SA, Fundación bancaria “La Caixa”, Fundació ACE,
and CIBERNED. A.R. and M.B. receive support from the European Union/EFPIA
Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects
(grant numbers 115975 and 115985, respectively). M.B. and A.R. are also supported by
national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240 and PI19/01301.
Acción Estratégica en Salud is integrated into the Spanish National R + D + I Plan and
funded by ISCIII (Instituto de Salud Carlos III)—Subdirección General de Evaluación
and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de hacer
Europa”). The Alzheimer Center Amsterdam is supported by Stichting
Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was
developed with funding from Stichting Dioraphte. Genotyping of the Dutch case-control
samples was performed in the context of EADB (European Alzheimer DNA biobank)
funded by the JPco-fuND FP-829-029 (ZonMW project number 733051061). 100-Plus
study. This work was supported by Stichting Alzheimer
Nederland (WE09.2014-03), Stichting Diorapthe, horstingstuit foundation, Memorabel
(ZonMW project number 733050814, 733050512) and Stichting VUmc Fonds. Genotyping of the 100-Plus Study was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW project numb 733051061). Longitudinal Aging Study Amsterdam (LASA) is largely supported by a
grant from the Netherlands Ministry of Health, Welfare and Sports, Directorate of LongTerm Care. This work was supported by a
grant (European Alzheimer DNA BioBank, EADB) from the EU Joint Program—Neurodegenerative Disease Research (JPND) and also funded by Inserm, Institut Pasteur de
Lille, the Lille Métropole Communauté Urbaine, the French government’s LABEX
DISTALZ program (development of innovative strategies for a transdisciplinary
approach to AD). Genotyping of the German case-control samples was performed in the
context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND
(German Federal Ministry of Education and Research, BMBF: 01ED1619A). The i–Select chips was funded by the French National Foundation on AD and
related disorders. EADI was supported by the LABEX (laboratory of excellence program
investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Université
de Lille 2 and the Lille University Hospital. GERAD was supported by the Medical
Research Council (Grant n° 503480), Alzheimer’s Research UK (Grant n° 503176), the
Wellcome Trust (Grant n° 082604/2/07/Z) and German Federal Ministry of Education
and Research (BMBF): Competence Network Dementia (CND) grant n° 01GI0102,
01GI0711, 01GI0420. CHARGE was partly supported by the NIA/NHLBI grants
AG049505, AG058589, HL105756 and AGES contract N01–AG–12100, the Icelandic
Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was
supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01 AG016976, and
the Alzheimer’s Association grant ADGC–10–19672
Genomic characterization of host factors related to SARS-CoV-2 infection in people with dementia and control populations: the GR@ACE/DEGESCO study
Emerging studies have suggested several chromosomal regions as potential host genetic factors involved in the susceptibility to SARS-CoV-2 infection and disease outcome. We nested a COVID-19 genome-wide association study using the GR@ACE/DEGESCO study, searching for susceptibility factors associated with COVID-19 disease. To this end, we compared 221 COVID-19 confirmed cases with 17,035 individuals in whom the COVID-19 disease status was unknown. Then, we performed a meta-analysis with the publicly available data from the COVID-19 Host Genetics Initiative. Because the APOE locus has been suggested as a potential modifier of COVID-19 disease, we added sensitivity analyses stratifying by dementia status or by disease severity. We confirmed the existence of the 3p21.31 region (LZTFL1, SLC6A20) implicated in the susceptibility to SARS-CoV-2 infection and TYK2 gene might be involved in COVID-19 severity. Nevertheless, no statistically significant association was observed in the COVID-19 fatal outcome or in the stratified analyses (dementia-only and non-dementia strata) for the APOE locus not supporting its involvement in SARS-CoV-2 pathobiology or COVID-19 prognosis
Epilepsy in neurodegenerative diseases: related drugs and molecular pathways
Epilepsy is a chronic disease of the central nervous system characterized by an electrical imbalance in neurons. It is the second most prevalent neurological disease, with 50 million people affected around the world, and 30% of all epilepsies do not respond to available treatments. Currently, the main hypothesis about the molecular processes that trigger epileptic seizures and promote the neurotoxic effects that lead to cell death focuses on the exacerbation of the glutamate pathway and the massive influx of Ca2+ into neurons by different factors. However, other mechanisms have been proposed, and most of them have also been described in other neurodegenerative diseases, such as Alzheimers disease, Parkinsons disease, Huntingtons disease, or multiple sclerosis. Interestingly, and mainly because of these common molecular links and the lack of effective treatments for these diseases, some antiseizure drugs have been investigated to evaluate their therapeutic potential in these pathologies. Therefore, in this review, we thoroughly investigate the common molecular pathways between epilepsy and the major neurodegenerative diseases, examine the incidence of epilepsy in these populations, and explore the use of current and innovative antiseizure drugs in the treatment of refractory epilepsy and other neurodegenerative diseases.Acknowledges the support of the Spanish Ministry of Science, Innovation
and Universities under the grant Juan de la Cierva (FJC2018-036012-I). Authors acknowledge the
support of the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated into
the Spanish National R+D+I Plan and financed by ISCIII Subdirección General de Evaluación
and the Fondo Europeo de Desarrollo Regional (FEDER “Una manera de hacer Europa”) grant
PI17/01474 awarded to M.B. Boada and grant PI19/00335 awarded to M.M.; M.E. acknowledges
the support of the Spanish Ministry of Economy and Competitiveness under the project SAF2017-
84283-R, and CIBERNED under project CB06/05/0024. E.B.S. acknowledges the support of the
Portuguese Science and Technology Foundation (FCT) for the strategic fund (UIDB/04469/2020).
A.R. acknowledges the support of CIBERNED (Instituto de Salud Carlos III (ISCIII)), the EU/EFPIA
Innovative Medicines Initiative Joint Undertaking, ADAPTED Grant Nº 115975, from EXIT project, EU
Euronanomed3 Program JCT2017 Grant Nº AC17/00100, from PREADAPT project. Joint Program
for Neurodegenerative Diseases (JPND) Grant No. AC19/00097, and from grants PI13/02434,
PI16/01861 BA19/00020, and PI19/01301. Acción Estratégica en Salud, integrated in the Spanish
National RCDCI Plan and financed by Instituto de Salud Carlos III (ISCIII)- Subdirección General
de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de Hacer
Europa”), by Fundación bancaria “La Caixa” and Grífols SA (GR@ACE project)info:eu-repo/semantics/publishedVersio
Long runs of homozygosity are associated with Alzheimer’s disease
Long runs of homozygosity (ROH) are contiguous stretches of homozygous genotypes, which are a footprint of
inbreeding and recessive inheritance. The presence of recessive loci is suggested for Alzheimer’s disease (AD);
however, their search has been poorly assessed to date. To investigate homozygosity in AD, here we performed a finescale
ROH analysis using 10 independent cohorts of European ancestry (11,919 AD cases and 9181 controls.) We
detected an increase of homozygosity in AD cases compared to controls [βAVROH (CI 95%) = 0.070 (0.037–0.104); P =
3.91 × 10−5; βFROH (CI95%) = 0.043 (0.009–0.076); P = 0.013]. ROHs increasing the risk of AD (OR > 1) were significantly
overrepresented compared to ROHs increasing protection (p < 2.20 × 10−16). A significant ROH association with AD risk
was detected upstream the HS3ST1 locus (chr4:11,189,482‒11,305,456), (β (CI 95%) = 1.09 (0.48 ‒ 1.48), p value =
9.03 × 10−4), previously related to AD. Next, to search for recessive candidate variants in ROHs, we constructed a
homozygosity map of inbred AD cases extracted from an outbred population and explored ROH regions in wholeexome
sequencing data (N = 1449). We detected a candidate marker, rs117458494, mapped in the SPON1 locus, which
has been previously associated with amyloid metabolism. Here, we provide a research framework to look for recessive
variants in AD using outbred populations. Our results showed that AD cases have enriched homozygosity, suggesting
that recessive effects may explain a proportion of AD heritability.Consejería de Salud de la Junta de Andalucía PI-0001/201
Genome Wide Meta-Analysis identifies common genetic signatures shared by heart function and Alzheimer's disease
Echocardiography has become an indispensable tool for the study of heart performance, improving the monitoring of individuals with cardiac diseases. Diverse genetic factors associated with echocardiographic measures have been previously reported. The impact of several apoptotic genes in heart development identified in experimental models prompted us to assess their potential association with human cardiac function. This study aimed at investigating the possible association of variants of apoptotic genes with echocardiographic traits and to identify new genetic markers associated with cardiac function. Genome wide data from different studies were obtained from public repositories. After quality control and imputation, a meta-analysis of individual association study results was performed. Our results confirmed the role of caspases and other apoptosis related genes with cardiac phenotypes. Moreover, enrichment analysis showed an over-representation of genes, including some apoptotic regulators, associated with Alzheimer's disease. We further explored this unexpected observation which was confirmed by genetic correlation analyses. Our findings show the association of apoptotic gene variants with echocardiographic indicators of heart function and reveal a novel potential genetic link between echocardiographic measures in healthy populations and cognitive decline later on in life. These findings may have important implications for preventative strategies combating Alzheimer's disease
Epilepsy in Neurodegenerative Diseases: Related Drugs and Molecular Pathways
Epilepsy is a chronic disease of the central nervous system characterized by an electrical imbalance in neurons. It is the second most prevalent neurological disease, with 50 million people affected around the world, and 30% of all epilepsies do not respond to available treatments. Currently, the main hypothesis about the molecular processes that trigger epileptic seizures and promote the neurotoxic effects that lead to cell death focuses on the exacerbation of the glutamate pathway and the massive influx of Ca2+ into neurons by different factors. However, other mechanisms have been proposed, and most of them have also been described in other neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, or multiple sclerosis. Interestingly, and mainly because of these common molecular links and the lack of effective treatments for these diseases, some antiseizure drugs have been investigated to evaluate their therapeutic potential in these pathologies. Therefore, in this review, we thoroughly investigate the common molecular pathways between epilepsy and the major neurodegenerative diseases, examine the incidence of epilepsy in these populations, and explore the use of current and innovative antiseizure drugs in the treatment of refractory epilepsy and other neurodegenerative diseases. Keywords: Alzheimer's disease; Huntington's disease; Parkinson's disease; epilepsy; multiple sclerosis; neurodegenerative diseases
- …